Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.

Garcia-Gomez A, Quwaider D, Canavese M, Ocio EM, Tian Z, Blanco JF, Berger AJ, Ortiz-de-Solorzano C, Hernández-Iglesias T, Martens AC, Groen RW, Mateo-Urdiales J, Fraile S, Galarraga M, Chauhan D, San Miguel JF, Raje N, Garayoa M.

Clin Cancer Res. 2014 Mar 15;20(6):1542-54. doi: 10.1158/1078-0432.CCR-13-1657. Epub 2014 Jan 31.

2.

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC.

Clin Cancer Res. 2011 Aug 15;17(16):5311-21. doi: 10.1158/1078-0432.CCR-11-0476. Epub 2011 Jun 30.

3.

Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.

Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S.

Clin Cancer Res. 2011 Dec 1;17(23):7313-23. doi: 10.1158/1078-0432.CCR-11-0636. Epub 2011 Sep 8.

4.

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN.

Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5.

5.

Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.

Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaissé JM.

Leuk Res. 2008 Nov;32(11):1661-8. doi: 10.1016/j.leukres.2008.02.019. Epub 2008 Apr 18.

PMID:
18394701
6.

Ixazomib for the treatment of multiple myeloma.

Gentile M, Offidani M, Vigna E, Corvatta L, Recchia AG, Morabito L, Morabito F, Gentili S.

Expert Opin Investig Drugs. 2015;24(9):1287-98. doi: 10.1517/13543784.2015.1065250. Epub 2015 Jul 3. Review.

PMID:
26138345
7.

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

Richardson PG, Moreau P, Laubach JP, Gupta N, Hui AM, Anderson KC, San Miguel JF, Kumar S.

Future Oncol. 2015;11(8):1153-68. doi: 10.2217/fon.15.9. Review.

PMID:
25832873
8.

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.

Garcia-Gomez A, Ocio EM, Crusoe E, Santamaria C, Hernández-Campo P, Blanco JF, Sanchez-Guijo FM, Hernández-Iglesias T, Briñón JG, Fisac-Herrero RM, Lee FY, Pandiella A, San Miguel JF, Garayoa M.

PLoS One. 2012;7(4):e34914. doi: 10.1371/journal.pone.0034914. Epub 2012 Apr 23.

9.

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.

Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J.

Cancer Res. 2010 Mar 1;70(5):1970-80. doi: 10.1158/0008-5472.CAN-09-2766. Epub 2010 Feb 16. Erratum in: Cancer Res. 2010 May 1;70(9):3853. Hales, Paul [added].

10.

MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.

Gu JJ, Hernandez-Ilizaliturri FJ, Mavis C, Czuczman NM, Deeb G, Gibbs J, Skitzki JJ, Patil R, Czuczman MS.

Anticancer Drugs. 2013 Nov;24(10):1030-8. doi: 10.1097/CAD.0000000000000008.

PMID:
23995855
11.

Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.

Engür S, Dikmen M, Öztürk Y.

Immunopharmacol Immunotoxicol. 2016;38(2):87-97. doi: 10.3109/08923973.2015.1122616. Epub 2015 Dec 15.

PMID:
26667773
12.

The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.

Engür S, Dikmen M.

Acta Clin Belg. 2017 Mar 22:1-8. doi: 10.1080/17843286.2017.1302623. [Epub ahead of print]

PMID:
28327055
13.

Oral ixazomib maintenance therapy in multiple myeloma.

Offidani M, Corvatta L, Gentili S, Maracci L, Leoni P.

Expert Rev Anticancer Ther. 2016;16(1):21-32. doi: 10.1586/14737140.2016.1123627. Review.

PMID:
26588946
14.

The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.

Paulus A, Masood A, Miller KC, Khan AN, Akhtar D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K, Chanan-Khan A.

Br J Haematol. 2014 Apr;165(1):78-88. doi: 10.1111/bjh.12731. Epub 2014 Jan 27.

PMID:
24467634
15.

Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.

Polzer K, Neubert K, Meister S, Frey B, Baum W, Distler JH, Gückel E, Schett G, Voll RE, Zwerina J.

Arthritis Rheum. 2011 Mar;63(3):670-80. doi: 10.1002/art.30177.

16.

The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.

Kaiser MF, Heider U, Mieth M, Zang C, von Metzler I, Sezer O.

Eur J Haematol. 2013 Apr;90(4):263-72. doi: 10.1111/ejh.12069. Epub 2013 Feb 15.

PMID:
23311753
17.
18.

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.

Tian Z, Zhao JJ, Tai YT, Amin SB, Hu Y, Berger AJ, Richardson P, Chauhan D, Anderson KC.

Blood. 2012 Nov 8;120(19):3958-67. doi: 10.1182/blood-2012-01-401794. Epub 2012 Sep 14.

19.

Bortezomib inhibits human osteoclastogenesis.

von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M, Kaiser M, Jakob C, Sterz J, Kleeberg L, Heider U, Sezer O.

Leukemia. 2007 Sep;21(9):2025-34. Epub 2007 Jun 21.

PMID:
17581612
20.

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.

Park J, Park E, Jung CK, Kang SW, Kim BG, Jung Y, Kim TH, Lim JY, Lee SE, Min CK, Won KA.

BMC Cancer. 2016 Mar 24;16:247. doi: 10.1186/s12885-016-2285-2.

Supplemental Content

Support Center